Biologikanebenwirkungen bei Psoriasis

BACKGROUND: The introduction of biologics has revolutionized the treatment of moderate to severe plaque psoriasis. Due to the continuous expansion of biological therapies for psoriasis, it is particularly important to acknowledge efficacy and safety of the compounds not only in clinical trials but also in long-term registry-based observational studies.

AIM: Typical side effects and significant risks of antipsoriatic biologic therapies considering psoriatic control groups are presented.

MATERIALS AND METHODS: A selective literature search was conducted in PubMed and long-term safety studies of the psoriasis registries PsoBest, PSOLAR and BADBIR were evaluated.

RESULTS AND DISCUSSION: To assess the long-term safety of biologics, the evaluation of the course of large patient cohorts in long-term registries is of particular medical importance. Newer biologic drugs seem to exhibit a better safety profile than older ones.